Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 818CNS 115Thoracic 95Sarcoma 79Other solid neoplasm 75Tumor-Agnostic 40Breast 34Gynecologic 23Genitourinary 21Lymphoid 13Dermatologic 10Other hematologic neoplasm 9Head & Neck 9Endocrine 9NET 3Plasma cell 1Other neoplasm 1Myeloid 1Classical hematology 1

Conditions

Advanced Malignant Neoplasm 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Biopsy 9fludarabine phosphate 8Busulfan 8Whole-Body Irradiation 7Surveys and Questionnaires 6Mycophenolic Acid 6Educational Status 6Early Intervention, Educational 6Carboplatin 6fludarabine 5Tacrolimus 5Paclitaxel 5Methotrexate 5Methods 5Melphalan 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Colposcopy 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4Selenium 4Radiotherapy 4Patient Reported Outcome Measures 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Irinotecan × Other neoplasm × Clear all
NCT06394713 2024-05-01

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
60 enrolled
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡